Last reviewed · How we verify
NCT01579994
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Phase 1 trial testing Ganetespib (STA-9090) and crizotinib in Advanced Lung Cancer in 13 participants. Completed in 28 December 2020.
28 December 2020
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 16 April 2012 |
| Primary completion | 28 December 2020 |
| Estimated completion | 28 December 2020 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- Ganetespib (STA-9090) and crizotinib — full drug profile →
Conditions studied
- Advanced Lung Cancer — all drugs for Advanced Lung Cancer →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Advanced Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
About 18 patients will take part in the phase 1 portion of the trial. In the beginning of the study, 3 patients will be treated with a low dose of ganetespib (STA-9090) and the standard dose of crizotinib. If this dose does not cause significant side effects, it will be increased as new patients take part in the study. The study will only be open at Memorial Sloan Kettering Cancer Center.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities.
Hu C, Yang J, Qi Z, Wu H, et al · · 2022 · cited 441× · PMID 35928554 · DOI 10.1002/mco2.161 -
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Schram AM, Chang MT, Jonsson P, Drilon A. · · 2017 · cited 270× · PMID 28857077 · DOI 10.1038/nrclinonc.2017.127 -
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B, Luu A, Jones R, Viloria-Petit AM. · · 2018 · cited 197× · PMID 29455675 · DOI 10.1186/s12943-018-0810-4 -
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad MM, Shaw AT. · · 2014 · cited 186× · PMID 25322323 -
Molecular pathways and therapeutic targets in lung cancer.
Shtivelman E, Hensing T, Simon GR, Dennis PA, et al · · 2014 · cited 150× · PMID 24722523 · DOI 10.18632/oncotarget.1891 -
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I, Planchard D. · · 2016 · cited 89× · PMID 26753004 · DOI 10.1177/1758834015617355 -
Ganetespib: research and clinical development.
Jhaveri K, Modi S. · · 2015 · cited 70× · PMID 26244021 · DOI 10.2147/ott.s65804 -
Heat shock protein 90: biological functions, diseases, and therapeutic targets.
Wei H, Zhang Y, Jia Y, Chen X, et al · · 2024 · cited 54× · PMID 38283176 · DOI 10.1002/mco2.470
Verify or expand the search:
- PubMed search for NCT01579994
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Lung Cancer
Currently open trials in the same condition.
- NCT07227623 — A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors · NA · recruiting
- NCT06992583 — Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer · Phase 1 · recruiting
- NCT06945523 — Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advan · Phase 1 · recruiting
- NCT06903117 — Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma · Phase 1 · recruiting
- NCT06928922 — Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. · EARLY_PHASE1 · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01579994 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 30 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01579994.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing